Tags

Type your tag names separated by a space and hit enter

Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.
Bone Marrow Transplant. 2003 Oct; 32(7):695-701.BM

Abstract

Since the incidence of cytomegalovirus (CMV) infections after hematopoietic stem cell transplantation (HSCT) may depend on the intensity of the pretreatment, we studied the incidence of CMV infections after reduced-intensity compared to myeloablative conditioning. A total of 82 patients with matched related or unrelated donors were prospectively monitored for CMV infections after HSCT by CMV-PCR techniques, CMV-antigenemia and clinical observation. A total of 45 patients received reduced-intensity conditioning consisting of fludarabine, busulfan and ATG and 37 patients received myeloablative conditioning. Leukocyte engraftment occurred after a median of 15 vs 18 days (P=0.012) and platelet engraftment after 12 days vs 20 days (P=0.001), respectively. Acute graft-versus-host disease (GVHD) grade II-IV was observed in 58 vs 54% patients (P=0.737), respectively. The onset and peak values of CMV-antigenemia and DNAemia and the incidence of CMV infections did not differ statistically significantly between the two treatment groups. Multivariate analysis confirmed CMV seropositivity of the recipient (P=0.035), acute GVHD II-IV (P=0.001) but not the type of conditioning as significant risk factors for CMV-antigenemia. In conclusion, the kinetics of CMV-antigenemia and DNAemia and the incidence of CMV infections were not statistically different in patients who received HSCT after reduced-intensity conditioning with fludarabine, busulfan and ATG compared to myeloablative conditioning.

Authors+Show Affiliations

Charité Campus Virchow Klinikum, Humboldt-Universität zu Berlin, Medizinische Klinik m.S. Hämatologie und Onkologie, Berlin, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

13130317

Citation

Schetelig, J, et al. "Cytomegalovirus Infections in Allogeneic Stem Cell Recipients After Reduced-intensity or Myeloablative Conditioning Assessed By Quantitative PCR and Pp65-antigenemia." Bone Marrow Transplantation, vol. 32, no. 7, 2003, pp. 695-701.
Schetelig J, Oswald O, Steuer N, et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant. 2003;32(7):695-701.
Schetelig, J., Oswald, O., Steuer, N., Radonic, A., Thulke, S., Held, T. K., Oertel, J., Nitsche, A., & Siegert, W. (2003). Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplantation, 32(7), 695-701.
Schetelig J, et al. Cytomegalovirus Infections in Allogeneic Stem Cell Recipients After Reduced-intensity or Myeloablative Conditioning Assessed By Quantitative PCR and Pp65-antigenemia. Bone Marrow Transplant. 2003;32(7):695-701. PubMed PMID: 13130317.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. AU - Schetelig,J, AU - Oswald,O, AU - Steuer,N, AU - Radonic,A, AU - Thulke,S, AU - Held,T K, AU - Oertel,J, AU - Nitsche,A, AU - Siegert,W, PY - 2003/9/18/pubmed PY - 2004/6/24/medline PY - 2003/9/18/entrez SP - 695 EP - 701 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 32 IS - 7 N2 - Since the incidence of cytomegalovirus (CMV) infections after hematopoietic stem cell transplantation (HSCT) may depend on the intensity of the pretreatment, we studied the incidence of CMV infections after reduced-intensity compared to myeloablative conditioning. A total of 82 patients with matched related or unrelated donors were prospectively monitored for CMV infections after HSCT by CMV-PCR techniques, CMV-antigenemia and clinical observation. A total of 45 patients received reduced-intensity conditioning consisting of fludarabine, busulfan and ATG and 37 patients received myeloablative conditioning. Leukocyte engraftment occurred after a median of 15 vs 18 days (P=0.012) and platelet engraftment after 12 days vs 20 days (P=0.001), respectively. Acute graft-versus-host disease (GVHD) grade II-IV was observed in 58 vs 54% patients (P=0.737), respectively. The onset and peak values of CMV-antigenemia and DNAemia and the incidence of CMV infections did not differ statistically significantly between the two treatment groups. Multivariate analysis confirmed CMV seropositivity of the recipient (P=0.035), acute GVHD II-IV (P=0.001) but not the type of conditioning as significant risk factors for CMV-antigenemia. In conclusion, the kinetics of CMV-antigenemia and DNAemia and the incidence of CMV infections were not statistically different in patients who received HSCT after reduced-intensity conditioning with fludarabine, busulfan and ATG compared to myeloablative conditioning. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/13130317/Cytomegalovirus_infections_in_allogeneic_stem_cell_recipients_after_reduced_intensity_or_myeloablative_conditioning_assessed_by_quantitative_PCR_and_pp65_antigenemia_ L2 - https://doi.org/10.1038/sj.bmt.1704164 DB - PRIME DP - Unbound Medicine ER -